{"id":67170,"date":"2023-03-09T04:00:12","date_gmt":"2023-03-09T04:00:12","guid":{"rendered":"http:\/\/malaysiantribune.com\/?guid=0abf366962b1e55e6c2b71eecda418c9"},"modified":"2023-03-09T04:00:12","modified_gmt":"2023-03-09T04:00:12","slug":"nyxoah-to-release-fourth-quarter-and-full-year-2022-financial-results-on-march-22-2023","status":"publish","type":"post","link":"https:\/\/malaysiantribune.com\/nyxoah-to-release-fourth-quarter-and-full-year-2022-financial-results-on-march-22-2023\/","title":{"rendered":"Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023"},"content":{"rendered":"
\n

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results\u00a0on March\u00a022, 2023<\/b><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 March 8, 2023, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/b>\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET \/ 4:30pm ET.<\/p>\n

Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link:\u00a0\u00a0Conference Registration (vevent.com)<\/u><\/a>. A live and archived webcast of the event will be available on the Company\u2019s investor relations website at\u00a0https:\/\/investors.nyxoah.com\/events<\/u><\/a>.<\/p>\n

About Nyxoah<\/b>
\nNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio\u00ae system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.<\/p>\n

For more information, please visit\u00a0http:\/\/www.nyxoah.com\/<\/u><\/a>.<\/p>\n

Caution\u00a0<\/b>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

Contacts:<\/b>
\nNyxoah<\/b>
\nDavid DeMartino, Chief Strategy Officer
\ndavid.demartino@nyxoah.com<\/u><\/a>
\n+1 310 310 1313<\/p>\n

Attachment<\/strong><\/p>\n